The new investment will go towards the areas of cancer, inherited diseases, and infectious diseases, with an initial focus on pediatric cancer.
RXi Pharmaceuticals this week released data from a phase I trial of its dermal anti-scarring drug RXI-109, showing that the compound was safe and well-tolerated.
By a GenomeWeb staff reporter
By Monica Heger
In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.
A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.
There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.
Stat News reports that Joseph Gulfo is another contender for FDA commissioner.